Literature DB >> 32191142

Enrollment and transition challenges in the International Maternal Pediatric and Adolescent AIDS Clinical Trials (IMPAACT) network's PROMISE trial for resource-limited regions.

Konstantia Angelidou1, Mary Glenn Fowler2, Pat Flynn3, Anne Coletti4, Katie McCarthy4, Renee Browning5, James McIntyre6,7, Sean S Brummel1, David E Shapiro1, Camlin Tierney1.   

Abstract

BACKGROUND: We describe enrollment and accrual challenges in the "Promoting Maternal and Infant Survival Everywhere" (PROMISE) trial conducted in resource-limited countries, as well as the challenges in transitioning participants from the antepartum to the postpartum components of the study.
METHODS: PROMISE was a large multi-national randomized controlled trial of the safety and efficacy of interventions to reduce perinatal transmission of HIV-1 (HIV) during pregnancy and breastfeeding and of interventions to preserve maternal health after cessation of perinatal transmission risk. The PROMISE study included two protocols for HIV-infected pregnant women in resource-limited countries who intended to either breastfeed or formula-feed their infants and did not meet country criteria for antiretroviral treatment. The PROMISE breastfeeding protocol (1077BF) used a sequential randomization design with up to three randomizations (Antepartum, Postpartum, and Maternal Health). The PROMISE formula-feeding protocol (1077FF) had two randomizations (Antepartum and Maternal Health). Women presenting to the clinic during early or active labor or in the immediate postpartum period were registered as Late Presenters and screened to determine whether eligible to participate in the Postpartum randomization.
RESULTS: The study was conducted at 14 sites in seven countries and opened to enrollment in April 2011. A total of 3259 pregnant women intending to breastfeed and an additional 284 pregnant women intending to formula feed were randomized in the Antepartum component. A total of 204 Late Presenters were registered during labor or after delivery. Enrollment was high among breastfeeding women (representing 96% of the target of 3400 women) but was lower than expected among women intending to formula feed (28% of 1000 expected) and late-presenting women (8% of 2500 expected). The successful overall enrollment and final primary study analyses results were attributed to substantial preparation before the study opened, collaboration among all stakeholders, close study monitoring during implementation and the flexibility to change and streamline the protocol.
CONCLUSIONS: Experiences from the PROMISE study illustrate the challenges of enrolling in longer term studies in the setting of rapidly evolving prevention and treatment standards priorities. The lessons learned will help the community, site investigators, and study coordinators in the design and implementation of future clinical trials.

Entities:  

Keywords:  AIDS; HIV-1; PROMISE study; antiretroviral therapy; enrollment; prevention of perinatal transmission; randomized clinical trial; resource-limited settings

Mesh:

Substances:

Year:  2020        PMID: 32191142      PMCID: PMC7415523          DOI: 10.1177/1740774520912428

Source DB:  PubMed          Journal:  Clin Trials        ISSN: 1740-7745            Impact factor:   2.486


  5 in total

1.  Maternal health outcomes among HIV-infected breastfeeding women with high CD4 counts: results of a treatment strategy trial.

Authors:  Risa M Hoffman; Konstantia Nadia Angelidou; Sean S Brummel; Friday Saidi; Avy Violari; Dingase Dula; Vidya Mave; Lee Fairlie; Gerhard Theron; Moreen Kamateeka; Tsungai Chipato; Benjamin H Chi; Lynda Stranix-Chibanda; Teacler Nematadzira; Dhayendre Moodley; Debika Bhattacharya; Amita Gupta; Anne Coletti; James A McIntyre; Karin L Klingman; Nahida Chakhtoura; David E Shapiro; Mary Glenn Fowler; Judith S Currier
Journal:  HIV Clin Trials       Date:  2018-12

2.  Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial.

Authors:  Beatriz Grinsztejn; Mina C Hosseinipour; Heather J Ribaudo; Susan Swindells; Joseph Eron; Ying Q Chen; Lei Wang; San-San Ou; Maija Anderson; Marybeth McCauley; Theresa Gamble; Nagalingeshwaran Kumarasamy; James G Hakim; Johnstone Kumwenda; Jose H S Pilotto; Sheela V Godbole; Suwat Chariyalertsak; Marineide Gonçalves de Melo; Kenneth H Mayer; Susan H Eshleman; Estelle Piwowar-Manning; Joseph Makhema; Lisa A Mills; Ravindre Panchia; Ian Sanne; Joel Gallant; Irving Hoffman; Taha E Taha; Karin Nielsen-Saines; David Celentano; Max Essex; Diane Havlir; Myron S Cohen
Journal:  Lancet Infect Dis       Date:  2014-03-04       Impact factor: 25.071

3.  Prevention of HIV-1 Transmission Through Breastfeeding: Efficacy and Safety of Maternal Antiretroviral Therapy Versus Infant Nevirapine Prophylaxis for Duration of Breastfeeding in HIV-1-Infected Women With High CD4 Cell Count (IMPAACT PROMISE): A Randomized, Open-Label, Clinical Trial.

Authors:  Patricia M Flynn; Taha E Taha; Mae Cababasay; Mary Glenn Fowler; Lynne M Mofenson; Maxensia Owor; Susan Fiscus; Lynda Stranix-Chibanda; Anna Coutsoudis; Devasena Gnanashanmugam; Nahida Chakhtoura; Katie McCarthy; Cornelius Mukuzunga; Bonus Makanani; Dhayendre Moodley; Teacler Nematadzira; Bangini Kusakara; Sandesh Patil; Tichaona Vhembo; Raziya Bobat; Blandina T Mmbaga; Maysseb Masenya; Mandisa Nyati; Gerhard Theron; Helen Mulenga; Kevin Butler; David E Shapiro
Journal:  J Acquir Immune Defic Syndr       Date:  2018-04-01       Impact factor: 3.731

4.  Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention.

Authors:  Mary G Fowler; Min Qin; Susan A Fiscus; Judith S Currier; Patricia M Flynn; Tsungai Chipato; James McIntyre; Devasena Gnanashanmugam; George K Siberry; Anne S Coletti; Taha E Taha; Karin L Klingman; Francis E Martinson; Maxensia Owor; Avy Violari; Dhayendre Moodley; Gerhard B Theron; Ramesh Bhosale; Raziya Bobat; Benjamin H Chi; Renate Strehlau; Pendo Mlay; Amy J Loftis; Renee Browning; Terence Fenton; Lynette Purdue; Michael Basar; David E Shapiro; Lynne M Mofenson
Journal:  N Engl J Med       Date:  2016-11-03       Impact factor: 91.245

5.  Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.

Authors:  Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton
Journal:  N Engl J Med       Date:  2015-07-20       Impact factor: 91.245

  5 in total
  2 in total

1.  Maternal Human Immunodeficiency Virus (HIV) Drug Resistance Is Associated With Vertical Transmission and Is Prevalent in Infected Infants.

Authors:  Ceejay L Boyce; Tatiana Sils; Daisy Ko; Annie Wong-On-Wing; Ingrid A Beck; Sheila M Styrchak; Patricia DeMarrais; Camlin Tierney; Lynda Stranix-Chibanda; Patricia M Flynn; Taha E Taha; Maxensia Owor; Mary Glenn Fowler; Lisa M Frenkel
Journal:  Clin Infect Dis       Date:  2022-06-10       Impact factor: 20.999

2.  Brief Report: Impact of ART on Maternal Health After Cessation of Breastfeeding.

Authors:  Sean S Brummel; Taha E Taha; Konstantia Nadia Angelidou; Friday Saidi; Patience Atuhaire; Dingase Dula; Dhayendre Moodley; Allen Matubu; Gift Chareka; Neetal Nevrekar; Tichaona Vhembo; Lee Fairlie; Gerhard Theron; Pendo Mlay; Kathleen George; Michael Basar; Nahida Chakhtoura; Renee Browning; Mary Glenn Fowler; Judith S Currier
Journal:  J Acquir Immune Defic Syndr       Date:  2021-04-01       Impact factor: 3.771

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.